BiomX Reports Results Of Phase 2 Cosmetic Acne Study Showed Statistically Significant Improvement From Baseline Observed In Appearance Of Acne-prone Skin But No Meaningful Difference Demonstrated Relative To Vehicle
October 18, 7:08 AM
BiomX Inc. (NYSE:PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage cocktails that target specific pathogenic bacteria, today
The Daily Biotech Pulse: FDA Nod For Lilly, Regulus Slumps On Study Discontinuation, ObSeva Strikes Linzagolix Commercialization Deal
October 13, 7:46 AM
Here's a roundup of top developments in the biotech space over the last 24 hours.
August 16, 6:34 AM
BiomX (AMEX:PHGE) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.37) by 18.92 percent. This is a 11.11 percent decrease over losses of $(0.27) per share from the same
August 16, 4:04 AM
Companies Reporting Before The Bell • Entera Bio (NASDAQ:ENTX) is likely to report earnings for its second quarter. • Data Storage (NASDAQ:DTST) is expected to report earnings for its second quarter.